Accutane (Isotretinoin) Pre-Surgery Hold Window: How Long to Stop Before Your Procedure

The Label Names Resurfacing and Waxing, Not Surgery in General

Oral isotretinoin is a retinoid that inhibits sebaceous gland function and keratinization [1][2]. The Absorica label and the older Accutane-format label both say to avoid wax epilation and skin resurfacing procedures such as dermabrasion and laser during treatment and for at least 6 months afterward, because of scarring [1][2].

The instruction names two categories: resurfacing and wax epilation. It is not written as a six-month ban on every operation.

What a Review of 1,485 Procedures Found

In 2017, a systematic review with consensus recommendations was published in JAMA Dermatology. A panel covering pediatric dermatology, procedural dermatology, plastic surgery, scars, wound healing, acne and isotretinoin reviewed English-language literature from 1982 to 2017 and graded the evidence. Thirty-two relevant publications reported 1,485 procedures [3].

The panel found insufficient evidence to support delaying manual dermabrasion, superficial chemical peels, cutaneous surgery, laser hair removal, or fractional ablative and nonablative laser procedures for patients currently receiving or having recently completed isotretinoin. It concluded that mechanical dermabrasion and fully ablative laser are not recommended in the setting of systemic isotretinoin treatment [3].

So the published record has three groups: procedures the label names with a six-month hold, procedures the panel found no evidence-based reason to delay, and two procedures the panel advised against during isotretinoin treatment.

Where the Six Months Came From

The review describes the widely taught 6-to-12-month delay as based on three small case series from the mid-1980s [3]. One 1986 case series reported six patients who had dermabrasion while on or having recently completed isotretinoin. All six developed keloids in atypical locations, and the keloids eventually responded to topical or intralesional steroids. Its authors recommended delaying dermabrasion in patients taking or recently on isotretinoin [5].

Surgery, Peels and Lasers by Category

Incisional (cutaneous) surgery, superficial chemical peels, laser hair removal and fractional ablative and nonablative lasers sit in the group for which the panel found insufficient evidence to support a delay [3]. The review separated fractional lasers from fully ablative laser, which it advised against during treatment [3].

An absence of evidence for a delay is a statement about the evidence, not a finding that surgery during treatment is free of risk. The labels list abnormal wound healing, described as delayed healing or exuberant granulation tissue with crusting, among isotretinoin's adverse reactions [1][2]. The labels do not attach a hold interval to incisional surgery.

How a Course Is Timed

The label gives a course as 15 to 20 weeks: Absorica 0.5 to 1 mg/kg/day in two divided doses, or Absorica LD 0.4 to 0.8 mg/kg/day [1]. A second course is not recommended before a two-month wait [1]. Absorica and Absorica LD are not substitutable mg for mg because their bioavailability and recommended doses differ [1].

The label's six months are counted from the end of treatment, so the date of the last dose and the type of procedure are what determine which statement applies [1][2].

iPLEDGE and Procedures

For patients who can get pregnant, iPLEDGE includes pregnancy testing and prevention requirements, and the prescription must be obtained within 7 days of the pregnancy-test collection. Pharmacies dispense no more than a 30-day supply with no refills, and patients are told not to donate blood during treatment or for 1 month after stopping [1]. The iPLEDGE requirements described in the label and on FDA's page cover enrollment, pregnancy-risk controls, dispensing and blood donation. They do not specify a procedure-scheduling interval [1][4].